미국 · 보도자료 · DTIL · 2026-10-08 11:01
B형간염 치료제 PBGENE-HBV, 간학회 구두 발표 선정
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has been selected to deliver a late-breaking oral presentation at The Liver Meeting 2026, the 77th annual meeting of the American Association f
